We are live on ! Find out more
IART icon

Integra LifeSciences

13.98 USD
+0.54
4.02%
At close Updated Oct 12, 4:00 PM EDT
Pre-market
After hours
13.98
0.00
0%
1 day
4.02%
5 days
3.86%
1 month
-11.01%
3 months
-24.76%
6 months
36.52%
Year to date
16.4%
1 year
2.64%
5 years
-78.92%
10 years
-65.94%
 

About: Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.

Employees: 4,427

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 42.9%
Neutral 51.4%
Negative 5.7%
Neutral
GlobeNewsWire
6 days ago
INTEGRA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Integra LifeSciences Holdings Corporation on Behalf of Integra Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Integra (IART) To Contact Him Directly To Discuss Their Options
INTEGRA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Integra LifeSciences Holdings Corporation on Behalf of Integra Stockholders and Encourages Investors to Contact the Firm
Neutral
GlobeNewsWire
6 days ago
Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026
PRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2026 financial results on Wednesday, October 21, 2026, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.
Integra LifeSciences to Host Third Quarter 2026 Financial Results Conference Call on October 21, 2026
Neutral
GlobeNewsWire
7 days ago
INTEGRA LIFESCIENCES HOLDINGS CORPORATION INVESTIGATION: IART Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights
NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired Integra securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below, to learn more about your rights.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION INVESTIGATION: IART Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights
Neutral
GlobeNewsWire
7 days ago
Integra LifeSciences (NASDAQ: IART) Investor Alert: Johnson Fistel Investigates Following Flooding-Related Outlook Cuts and 21% Stock Decline
SAN DIEGO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, is investigating Integra LifeSciences Holdings Corporation (NASDAQ: IART) on behalf of investors who may have suffered losses. If you purchased Integra securities and suffered losses, please contact the firm to learn more about the investigation. There is no cost or obligation.
Integra LifeSciences (NASDAQ: IART) Investor Alert: Johnson Fistel Investigates Following Flooding-Related Outlook Cuts and 21% Stock Decline
Neutral
Newsfile Corp
8 days ago
Integra LifeSciences (IART) Investor Alert: Johnson Fistel Investigates Following Flooding-Related Outlook Cuts and 21% Stock Decline
San Diego, California--(Newsfile Corp. - October 4, 2026) - Johnson Fistel, PLLP, a leading stockholder rights law firm, is investigating Integra LifeSciences Holdings Corporation (NASDAQ: IART) on behalf of investors who may have suffered losses. If you purchased Integra securities and suffered losses, please contact the firm to learn more about the investigation.
Integra LifeSciences (IART) Investor Alert: Johnson Fistel Investigates Following Flooding-Related Outlook Cuts and 21% Stock Decline
Neutral
PRNewsWire
10 days ago
Integra LifeSciences Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Integra LifeSciences (IART)
A $4.3 million to $6.3 million gap between Integra's preliminary third-quarter revenue and the Wall Street estimate sent IART shares lower. SueWallSt notifies investors of a pending investigation into potential securities claims for shareholders who lost money.
Integra LifeSciences Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Integra LifeSciences (IART)
Negative
Proactive Investors
10 days ago
Integra LifeSciences lowers revenue and earnings outlook for 2026
Integra Lifesciences Holdings Corp (NASDAQ:IART) cut its 2026 revenue and adjusted earnings guidance after July flooding disrupted operations in Cincinnati, despite expectations for strong cash generation. The medical technology company now forecasts annual revenue of $1.634 billion to $1.654 billion, down from $1.654 billion to $1.695 billion.
Integra LifeSciences lowers revenue and earnings outlook for 2026
Neutral
GlobeNewsWire
10 days ago
Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance
PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certain unaudited preliminary third quarter results and an update to its full-year 2026 guidance.
Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance
Neutral
GlobeNewsWire
10 days ago
Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B
PRINCETON, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the launch of a proposed $600 million seven-year Senior Secured Term Loan B as part of a broader refinancing transaction.
Integra LifeSciences Announces Launch of $600 Million Senior Secured Term Loan B
Neutral
Zacks Investment Research
11 days ago
IART vs. PEN: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integra LifeSciences (IART) and Penumbra (PEN). But which of these two stocks offers value investors a better bang for their buck right now?
IART vs. PEN: Which Stock Is the Better Value Option?
Price charts implemented using Lightweight Charts™